Mahwah, NJ, November 2, 2005
– DOBI Medical International, Inc. (DBMI.OB) engaged The Investor
Relations Group of New York (IRG) for its corporate financial and public
relations.

Phillip Thomas, CEO of DOBI Medical International, said,
“At a time of increased awareness of the role of mammography, DOBI
Medical’s ComfortScan® system may enable an improved diagnosis of cancer
through the identification of abnormal neovascularization associated
with tumors, especially for women under 50.”

“We believe that IRG is strategically positioned to help
us explain the benefits of our ComfortScan system, which is currently
under clinical trials as an adjunct to mammography,” explained Thomas.

Dian Griesel, Ph.D., founder and CEO of The Investor
Relations Group, said, “We welcome DOBI Medical’s confidence in our
ability to effectively communicate to the financial community and the
media the importance of its dynamic optical breast-imaging system.”

About DOBI Medical International,
Inc.DOBI Medical is a developmental stage, medical imaging company
working to create a new means for the improved diagnosis of high risk
and malignant breast disease through the identification of abnormal
vascularization ("angiogenesis") associated with tumors. DOBI Medical
International’s first application of the technology is the ComfortScan
system, a gentle, noninvasive, and nonionizing, optical imaging system
designed to assist physicians in the identification and management of
breast disease. The ComfortScan system is intended to achieve this by
providing new, physiology-based imagery of abnormal vascularization in
the breast that is not readily available today. The ComfortScan system
has its CE Mark and UL for international sales, and DOBI Medical is a
certified ISO 9001:2000 and ISO 13485 company. The ComfortScan system is
not yet commercially available in the U.S. as it is limited by U.S. law
to investigational use as an adjunct to mammography until approved by
the FDA, which cannot be guaranteed.

About The Investor Relations Group
The Investor Relations Group, Inc., (IRG) founded in 1996, represents
select publicly traded companies, with a unique specialization for
assisting those in the small-cap sector. IRG arranges one-on-one
meetings for its portfolio companies with pre-qualified money managers
handling investment portfolios that range from $10 million to $10
billion+ selected from its proprietary contact base of over 33,000
qualified fund managers who have an investing history in small cap
stocks. IRG is a full-service corporate communications company offering
services for its portfolio companies that include writing all press
releases and shareholder communications and serving as primary contact
for the investing community. IRG also houses a full-service public
relations arm that specializes in building awareness of its companies
within the financial and trade media, as well as the public at large.
For further information, please visit the company’s website at
www.investorrelationsgroup.com.

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

Statements contained in this press release may contain
information that includes or is based upon certain "forward-looking
statements" relating to our business. These forward-looking statements
represent management's current judgment and assumptions, and can be
identified by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements are frequently accompanied by
the use of such words as "anticipates," "plans," "believes," "expects,"
"projects," "intends," and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
factors, including without limitation, those relating to our ability to
timely and successfully complete our patient clinical trials; our
ability to timely and successfully complete and submit our premarket
approval application to the FDA; the timely and final approval by the
FDA of our ComfortScan system as a adjunct to mammography, which
approval in the U.S. cannot be assured; the success of product
development and research efforts; our ability to timely meet U. S. and
foreign government laws and industry standards; our ability to meet U.S.
and foreign medical device quality regulation standards required to
maintain our CE Mark, and ISO, UL and FDA export certifications; our
ability to timely deliver our products into international markets; the
acceptance and use of our ComfortScan system by physicians, imaging
clinics, and patients; and our ability to obtain third party
reimbursement from U.S. and foreign government and private payers.
Any one of these or other risks, uncertainties, other factors, or any
inaccurate assumptions may cause actual results to be materially
different from those described herein or elsewhere by us. We caution
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of
these risks, uncertainties, and other factors are described in greater
detail in our filings from time to time with the Securities and Exchange
Commission, which we strongly urge you to read and consider, including
our 2004 Annual Report on Form 10-KSB, all of which may be accessed from
our website at igaot.pt. Subsequent written and oral
forward-looking statements attributable to us or to persons acting on
our behalf are expressly qualified in their entirety by the cautionary
statements set forth above and elsewhere in our reports filed with the
Securities and Exchange Commission. We expressly disclaim any intent or
obligation to update any forward-looking statements.